One year of omega 3 polyunsaturated fatty acid supplementation does not reduce circulating prothrombotic microvesicles in elderly subjects after suffering a myocardial infarction
Background & aims: Circulating microvesicles (cMV) are both effectors and biomarkers of cardiovascular disease (CVD), and the effects of omega 3 polyunsaturated fatty acids (n3 PUFA) in MV shedding are not yet well known. Therefore, we aimed to investigate the effects of long-term n3 PUFA supple...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:270212 |
| Acceso en línea: | https://ddd.uab.cat/record/270212 https://dx.doi.org/urn:doi:10.1016/j.clnu.2021.10.007 |
| Access Level: | acceso abierto |
| Palabra clave: | Microvesicles Omega 3 fatty acids EPA DHA Elderly Thrombosis |
| Sumario: | Background & aims: Circulating microvesicles (cMV) are both effectors and biomarkers of cardiovascular disease (CVD), and the effects of omega 3 polyunsaturated fatty acids (n3 PUFA) in MV shedding are not yet well known. Therefore, we aimed to investigate the effects of long-term n3 PUFA supplementation on cMV release from cells of the vascular compartment in elderly subjects at very high risk of CVD. Methods: We included 156 elderly patients 2-8 weeks after suffering an acute myocardial infarction from the OMEMI cohort. Subjects were randomly allocated to receive 930 mg EPA + 660 mg DHA (n3 PUFA intervention) or corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid) used as placebo daily for two years. At inclusion and after one-year follow-up, prothrombotic [annexin V (AV)] cMV derived from blood and vascular cells were phenotyped by flow cytometry. Results: No differences were observed in the levels of cMV between the randomized groups at inclusion in the study. After one-year follow-up, total AV, platelet-derived CD61/AV, and endothelial-derived CD31/AV and CD31/CD42b/AV cMV increased significantly in both groups. In the n3 PUFA supplemented group, platelet-derived CD62P/AV, CD42b/AV and CD31/CD42b/AV; leukocyte-derived CD62L/AV, CD45/AV, and CD11b/AV, as well as endothelial derived CD146/AV, CD62E/AV, and CD309/AV cMV also increased significantly. No significant differences were however, observed in the changes of cMV levels between groups. Conclusion: In elderly Norwegians who have suffered a recent acute myocardial infarction and treated as per guidelines, long-term supplementation with 1.8 g/day n3 PUFA does not modulate prothrombotic MV release from blood and vascular cells. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01841944. |
|---|